Syros Pharmaceuticals, Inc. (SYRS)

Market Cap	4.68M
Revenue (ttm)	386,000
Net Income (ttm)	-97.82M
Shares Out	26.83M
EPS (ttm)	-2.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	569,364
Open	0.180
Previous Close	0.176
Day's Range	0.168 - 0.180
52-Week Range	0.160 - 7.960
Beta	1.30
Analysts	Hold
Price Target	3.00 (+1,621.17%)
Earnings Date	Mar 26, 2025

About SYRS

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 30, 2016
• Employees: 68
• Stock Exchange: NASDAQ
• Ticker Symbol: SYRS
• Website: https://www.syros.com

Financial Performance

In 2023, Syros Pharmaceuticals's revenue was $9.94 million, a decrease of -33.23% compared to the previous year's $14.88 million. Losses were -$164.57 million, 73.9% more than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for SYRS stock is "Hold." The 12-month stock price forecast is $3.0, which is an increase of 1,621.17% from the latest price.

Price Target

$3.0

(1,621.17% upside)

Analyst Consensus: Hold